-
Je něco špatně v tomto záznamu ?
Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study
F. Cavanna, S. Muller, LA. de la Fuente, F. Zamberlan, M. Palmucci, L. Janeckova, M. Kuchar, C. Pallavicini, E. Tagliazucchi
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, randomizované kontrolované studie, práce podpořená grantem
NLK
Directory of Open Access Journals
od 2011
Free Medical Journals
od 2011
Nature Open Access
od 2011-04-01
PubMed Central
od 2011
Europe PubMed Central
od 2011
ProQuest Central
od 2011-04-01
Open Access Digital Library
od 2011-01-01
Health & Medicine (ProQuest)
od 2011-04-01
ROAD: Directory of Open Access Scholarly Resources
od 2011
- MeSH
- Agaricales * MeSH
- dvojitá slepá metoda MeSH
- halucinogeny * farmakologie MeSH
- lidé MeSH
- motivace MeSH
- psilocybin farmakologie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
The use of low sub-perceptual doses of psychedelics ("microdosing") has gained popularity in recent years. Although anecdotal reports claim multiple benefits associated with this practice, the lack of placebo-controlled studies severely limits our knowledge of microdosing and its effects. Moreover, research conducted in standard laboratory settings could fail to capture the motivation of individuals engaged or planning to engage in microdosing protocols, thus underestimating the likelihood of positive effects on creativity and cognitive function. We recruited 34 individuals starting to microdose with psilocybin mushrooms (Psilocybe cubensis), one of the materials most frequently used for this purpose. Following a double-blind placebo-controlled experimental design, we investigated the acute and short-term effects of 0.5 g of dried mushrooms on subjective experience, behavior, creativity (divergent and convergent thinking), perception, cognition, and brain activity. The reported acute effects were significantly more intense for the active dose compared to the placebo, but only for participants who correctly identified their experimental condition. These changes were accompanied by reduced EEG power in the theta band, together with preserved levels of Lempel-Ziv broadband signal complexity. For all other measurements there was no effect of microdosing except for few small changes towards cognitive impairment. According to our findings, low doses of psilocybin mushrooms can result in noticeable subjective effects and altered EEG rhythms, but without evidence to support enhanced well-being, creativity and cognitive function. We conclude that expectation underlies at least some of the anecdotal benefits attributed to microdosing with psilocybin mushrooms.
Department of Experimental Neurobiology National Institute of Mental Health Klecany Czech Republic
Latin American Brain Health Institute Universidad Adolfo Ibañez Santiago de Chile Chile
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22024943
- 003
- CZ-PrNML
- 005
- 20221031101116.0
- 007
- ta
- 008
- 221017s2022 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41398-022-02039-0 $2 doi
- 035 __
- $a (PubMed)35918311
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Cavanna, Federico $u Departamento de Física, Universidad de Buenos Aires and Instituto de Física de Buenos Aires (IFIBA - CONICET), Pabellón I, Ciudad Universitaria (1428), CABA, Buenos Aires, Argentina $u Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI), Montañeses 2325, C1428 CABA, Buenos Aires, Argentina
- 245 10
- $a Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study / $c F. Cavanna, S. Muller, LA. de la Fuente, F. Zamberlan, M. Palmucci, L. Janeckova, M. Kuchar, C. Pallavicini, E. Tagliazucchi
- 520 9_
- $a The use of low sub-perceptual doses of psychedelics ("microdosing") has gained popularity in recent years. Although anecdotal reports claim multiple benefits associated with this practice, the lack of placebo-controlled studies severely limits our knowledge of microdosing and its effects. Moreover, research conducted in standard laboratory settings could fail to capture the motivation of individuals engaged or planning to engage in microdosing protocols, thus underestimating the likelihood of positive effects on creativity and cognitive function. We recruited 34 individuals starting to microdose with psilocybin mushrooms (Psilocybe cubensis), one of the materials most frequently used for this purpose. Following a double-blind placebo-controlled experimental design, we investigated the acute and short-term effects of 0.5 g of dried mushrooms on subjective experience, behavior, creativity (divergent and convergent thinking), perception, cognition, and brain activity. The reported acute effects were significantly more intense for the active dose compared to the placebo, but only for participants who correctly identified their experimental condition. These changes were accompanied by reduced EEG power in the theta band, together with preserved levels of Lempel-Ziv broadband signal complexity. For all other measurements there was no effect of microdosing except for few small changes towards cognitive impairment. According to our findings, low doses of psilocybin mushrooms can result in noticeable subjective effects and altered EEG rhythms, but without evidence to support enhanced well-being, creativity and cognitive function. We conclude that expectation underlies at least some of the anecdotal benefits attributed to microdosing with psilocybin mushrooms.
- 650 12
- $a Agaricales $7 D000363
- 650 _2
- $a dvojitá slepá metoda $7 D004311
- 650 12
- $a halucinogeny $x farmakologie $7 D006213
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a motivace $7 D009042
- 650 _2
- $a psilocybin $x farmakologie $7 D011562
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Muller, Stephanie $u Departamento de Física, Universidad de Buenos Aires and Instituto de Física de Buenos Aires (IFIBA - CONICET), Pabellón I, Ciudad Universitaria (1428), CABA, Buenos Aires, Argentina
- 700 1_
- $a de la Fuente, Laura Alethia $u Departamento de Física, Universidad de Buenos Aires and Instituto de Física de Buenos Aires (IFIBA - CONICET), Pabellón I, Ciudad Universitaria (1428), CABA, Buenos Aires, Argentina $u Institute of Cognitive and Translational Neuroscience, INECO Foundation, Favaloro University, Buenos Aires, Argentina $1 https://orcid.org/0000000256891709
- 700 1_
- $a Zamberlan, Federico $u Departamento de Física, Universidad de Buenos Aires and Instituto de Física de Buenos Aires (IFIBA - CONICET), Pabellón I, Ciudad Universitaria (1428), CABA, Buenos Aires, Argentina $u Department of Cognitive Science and Artificial Intelligence, Tilburg University, Tilburg, the Netherlands
- 700 1_
- $a Palmucci, Matías $u Departamento de Física, Universidad de Buenos Aires and Instituto de Física de Buenos Aires (IFIBA - CONICET), Pabellón I, Ciudad Universitaria (1428), CABA, Buenos Aires, Argentina
- 700 1_
- $a Janeckova, Lucie $u Forensic Laboratory of Biologically Active Substances, Department of Chemistry of Natural Compounds, University of Chemistry and Technology Prague, Prague, Czech Republic
- 700 1_
- $a Kuchar, Martin $u Forensic Laboratory of Biologically Active Substances, Department of Chemistry of Natural Compounds, University of Chemistry and Technology Prague, Prague, Czech Republic $u Department of Experimental Neurobiology, National Institute of Mental Health, Klecany, Czech Republic $1 https://orcid.org/0000000276166352
- 700 1_
- $a Pallavicini, Carla $u Departamento de Física, Universidad de Buenos Aires and Instituto de Física de Buenos Aires (IFIBA - CONICET), Pabellón I, Ciudad Universitaria (1428), CABA, Buenos Aires, Argentina $u Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI), Montañeses 2325, C1428 CABA, Buenos Aires, Argentina
- 700 1_
- $a Tagliazucchi, Enzo $u Departamento de Física, Universidad de Buenos Aires and Instituto de Física de Buenos Aires (IFIBA - CONICET), Pabellón I, Ciudad Universitaria (1428), CABA, Buenos Aires, Argentina. tagliazucchi.enzo@googlemail.com $u Latin American Brain Health Institute (BrainLat), Universidad Adolfo Ibañez, Santiago de Chile, Chile. tagliazucchi.enzo@googlemail.com $1 https://orcid.org/0000000304219993
- 773 0_
- $w MED00177206 $t Translational psychiatry $x 2158-3188 $g Roč. 12, č. 1 (2022), s. 307
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35918311 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20221017 $b ABA008
- 991 __
- $a 20221031101112 $b ABA008
- 999 __
- $a ok $b bmc $g 1854571 $s 1176233
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 12 $c 1 $d 307 $e 20220802 $i 2158-3188 $m Translational psychiatry $n Transl Psychiatr $x MED00177206
- LZP __
- $a Pubmed-20221017